2563 — Beijing Biostar Pharmaceuticals Income Statement
0.000.00%
Last trade - 00:00- HK$1.48bn
- HK$929.82m
- CNY33.36m
Annual income statement for Beijing Biostar Pharmaceuticals, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.
2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | ARS | ARS |
| Standards: | HKAS | HKAS | HKAS | CAS |
| Status: | Final | Final | Final | Final |
| Revenue | ||||
| Total Revenue | 32.8 | 66.6 | 71.9 | 33.4 |
| Cost of Revenue | ||||
| Gross Profit | 23.9 | 46.8 | 61.1 | 29.7 |
| Selling / General / Administrative Expenses | ||||
| Research And Development | ||||
| Depreciation and Amortization | ||||
| Operating Interest Expense / Income | ||||
| Unusual Expense / Income | ||||
| Other Operating Expenses | ||||
| Total Operating Expenses | 193 | 256 | 216 | 168 |
| Operating Profit | -160 | -190 | -144 | -134 |
| Total Net Non Operating Interest Income / Expense | ||||
| Total Net Non Operating Interest Income / Expense | ||||
| Other Net Non Operating Costs | ||||
| Net Income Before Taxes | -161 | -190 | -144 | -131 |
| Provision for Income Taxes | ||||
| Net Income After Taxes | -161 | -190 | -144 | -131 |
| Net Income Before Extraordinary Items | ||||
| Net Income | -161 | -190 | -144 | -131 |
| Income Available to Common Shareholders Excluding Extraordinary Items | ||||
| Income Available to Common Shareholders Including Extraordinary Items | ||||
| Diluted Net Income | -161 | -190 | -144 | -131 |
| Diluted Weighted Average Shares | ||||
| Basic EPS Including Extraordinary Items | ||||
| Diluted EPS Including Extraordinary Items | ||||
| Diluted EPS Excluding Extraordinary Items | ||||
| Normalised Income Before Taxes | ||||
| Normalised Income After Taxes | ||||
| Normalised Income Available to Common Shareholders | ||||
| Diluted Normalised EPS | -0.44 | -0.505 | -0.338 | -0.352 |